New Brunswick, NJ
March 3, 2026
Hilton East Brunswick, - New Jersey
Join us on this knowledge sharing seminar, designed for biopharma companies developing injectable therapies considering the transition from vials to prefilled syringes (PFS) and ultimately to integrated drug–device combination (DDC) products.
Supported by industry-leading device platform providers, container and packaging specialists, and ISO-compliant testing experts, this seminar brings together the technical disciplines required to successfully bridge the clinical to commercial gap.
As injectable drug products advance through clinical trials, development teams face increasingly complex decisions that shape long-term commercial success. Choices surrounding formulation, container systems, devices, testing, and packaging often made during clinical development can significantly impact scalability, regulatory readiness, patient usability, and overall risk.
David O’Connell, Director Scientific Affairs, PCI Pharma Services
Paige Stroh, Technical Solutions Manager, Becton Dickinson
As the industry continues to move beyond traditional vial presentations, transitioning to prefilled syringes presents both significant opportunities and complex technical challenges from formulation science to device performance and patient experience.
Key subjects discussed:
Learn how holistic, early-stage alignment between formulation scientists, container partners and device teams can reduce development risk, prevent late-stage changes, and enable a smoother, faster transition to patient-ready PFS presentations.
Victor Gherdan, Associate Director Package Design, PCI Pharma Services
Paul Martinez, Head of Business Development, SHL Medical
As patient populations diversify and sustainability expectations rise, early design decisions have never been more critical. Discover how prioritizing patient needs, aligning technical realities, and environmental responsibility can lead to more robust, compliant, and scalable solutions.
Key learning points:
Bill Welch, Executive Director Market Development, PCI Pharma Services
James Ritchey, Industry Manager, ZwickRoell
With drug device combination products becoming more complex, robust functional testing is no longer optional – it’s essential for risk reduction, regulatory confidence and product lifecycle success.
Key topics covered:
This session will provide practical insight into building testing strategies that support quality, compliance and long-term manufacturability.
Dawn Manley, Director Global Technical Sales, PCI Pharma Services
With parenteral combination products experiencing rapid growth, the demand for flexibility and scalability from clinical through commercialization has never been greater.
Key areas explored:
Whether your program involves prefilled syringes, needles safety devices, autoinjectors, or pens, we will provide practical guidance to help you navigate today’s evolving manufacturing landscape with confidence.
All attendees will have the opportunity to engage directly with industry leaders and receive immediate responses to their questions. This real-time access to subject matter experts enables meaningful dialogue, deeper insights, and a truly dynamic event experience.
March 3, 2026
Hilton East Brunswick, - New Jersey
March 5, 2026
Royal Sonesta Hotel - Cambridge, MA
March 10, 2026
Embassy Suites - San Francisco Airport
March 12, 2026
Marriott San Diego - LaJolla
Learn what it truly takes to move beyond the vial from formulation and process development considerations and container closure interactions to device functionality, human factors, and lifecycle management.
Understand how patient needs, usability, ergonomics, and sustainability influence device and packaging design, and how early decisions impact scalability and compliance.
Gain clarity on key ISO standards and testing strategies that support process validation, batch release, and regulatory submissions for combination products.
Explore integrated manufacturing, assembly, packaging, and tech transfer approaches that reduce cost, time, and development risk as programs scale.
Engage face-to-face with experienced subject matter experts, ask program-specific questions, and learn from organizations supporting today’s leading drug–device platforms.
Learn how structured technical governance helps manage dependencies, mitigate risk, and maintain momentum across SFF, device assembly, packaging, and supply chain execution.
Learn more about our sterile capabilities that deliver quality, innovation, and reliability from development through commercialization.
Contact us today and talk to our expert customer services team about how we can support you with sterile drug development services.
Inspired by tomorrow, and with over 8000 people in 38 global GMP facilities, we support you from early-stage development through commercialization and beyond.